Free Trial

Design Therapeutics (DSGN) Stock Price, News & Analysis

Design Therapeutics logo
$4.59 -0.34 (-6.90%)
Closing price 03/25/2025 04:00 PM Eastern
Extended Trading
$4.75 +0.16 (+3.49%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Design Therapeutics Stock (NASDAQ:DSGN)

Key Stats

Today's Range
$4.49
$5.09
50-Day Range
$3.68
$5.33
52-Week Range
$3.15
$7.77
Volume
144,858 shs
Average Volume
213,875 shs
Market Capitalization
$260.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Moderate Buy

Company Overview

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Remove Ads

Design Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

DSGN MarketRank™: 

Design Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 776th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Design Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Design Therapeutics has received no research coverage in the past 90 days.

  • Read more about Design Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Design Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.16) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Design Therapeutics is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Design Therapeutics is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Design Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Design Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.46% of the float of Design Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Design Therapeutics has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Design Therapeutics has recently increased by 2.55%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Design Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Design Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.46% of the float of Design Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Design Therapeutics has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Design Therapeutics has recently increased by 2.55%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Design Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Design Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Design Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.20% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Design Therapeutics' insider trading history.
Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DSGN Stock News Headlines

Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.
Design Therapeutics price target raised to $5 from $4 at RBC Capital
Design Therapeutics (DSGN) Gets a Hold from RBC Capital
Design Therapeutics sees cash runway into 2029
See More Headlines

DSGN Stock Analysis - Frequently Asked Questions

Design Therapeutics' stock was trading at $6.17 at the start of the year. Since then, DSGN shares have decreased by 25.6% and is now trading at $4.59.
View the best growth stocks for 2025 here
.

Design Therapeutics, Inc. (NASDAQ:DSGN) posted its earnings results on Monday, March, 10th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04.

Design Therapeutics (DSGN) raised $228 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Top institutional shareholders of Design Therapeutics include Frazier Life Sciences Management L.P. (3.45%), Point72 Asset Management L.P. (3.28%), Driehaus Capital Management LLC (1.37%) and Geode Capital Management LLC (1.35%). Insiders that own company stock include Sr One Capital Fund I Aggregat, Simeon George, Rodney W Lappe, Joao Md Siffert, John P Schmid, Deepa Prasad and Arsani William.
View institutional ownership trends
.

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Design Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
3/10/2025
Today
3/26/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DSGN
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$12.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+74.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-66,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.96 per share
Price / Book
0.93

Miscellaneous

Free Float
38,955,000
Market Cap
$260.54 million
Optionable
Optionable
Beta
1.77
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:DSGN) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners